Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-007743
Filing Date
2025-05-14
Accepted
2025-05-14 16:06:12
Documents
53
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 LVTX 1Q25 10-Q lvtx-20250331x10q.htm   iXBRL 10-Q 826559
2 EX-31.1 lvtx-20250331xex31d1.htm EX-31.1 20497
3 EX-31.2 lvtx-20250331xex31d2.htm EX-31.2 18895
4 EX-32.1 lvtx-20250331xex32d1.htm EX-32.1 9078
5 EX-32.2 lvtx-20250331xex32d2.htm EX-32.2 9072
  Complete submission text file 0001558370-25-007743.txt   3143437

Data Files

Seq Description Document Type Size
6 EX-101.SCH lvtx-20250331.xsd EX-101.SCH 26911
7 EX-101.CAL lvtx-20250331_cal.xml EX-101.CAL 34710
8 EX-101.DEF lvtx-20250331_def.xml EX-101.DEF 64181
9 EX-101.LAB lvtx-20250331_lab.xml EX-101.LAB 220101
10 EX-101.PRE lvtx-20250331_pre.xml EX-101.PRE 166811
56 EXTRACTED XBRL INSTANCE DOCUMENT lvtx-20250331x10q_htm.xml XML 235556
Mailing Address YALELAAN 62 UTRECHT P7 3584 CM
Business Address YALELAAN 62 UTRECHT P7 3584 CM 31 6 3000 3035
LAVA Therapeutics NV (Filer) CIK: 0001840748 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40241 | Film No.: 25945376
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)